Novartis heart drug's trial failure cast doubt on Amgen and Lilly's cholesterol race
Pelacarsen lowered Lp(a) levels in more than 8,000 patients but did not reduce the risk of heart attacks, strokes, or cardiovascular death
We haven't written up this one. Quartz has the full story — the link below goes straight to it.